| Application no. and date | 21716724.6 (espacenet) (Federated) (European Patent Register), 20210401 | | Patent/reg. no. and date | DK/EP 4188389, 20250917 | | Publication date | 20230607 | | Priority no. and date | US 202063057139 P, 20200727, US 202063070869 P, 20200827, US 202063082524 P, 20200924, US 202063093961 P, 20201020, US 202063119711 P, 20201201, US 202163152445 P, 20210223, US 202163161629 P, 20210316 | | EP pub. no. and date |
EP 4188389 20230607 | | Effective date | | | Applicant/owner | AstraZeneca AB,
151 85 Södertälje, SE | | Applicant ref. no. | V495990DK00 | | Inventor | LANGKILDE, Anna Maria,
151 85 Södertälje, SE | | Representative | Zacco Denmark A/S, Arne Jacobsens Allé 15, 2300 København S | | Opponent | | | IPC Class | A61K 31/70 (2006.01) , A61P 31/12 (2006.01) | | Title | DAPAGLIFLOZIN TIL BRUG I FREMGANGSMÅDER TIL BEHANDLING AF KRONISK NYRESYGDOM | | Int. application no. | EP2021058727 | | Int. publication no. | WO2022022865 | | Related patent (certificate) | | | Status | DK/EP patent | | Pædiatrisk forlængelse | - | | Udløbsdato for pædiatrisk forlængelse | - |
|
